We found that blocking IL-1β with an IL-1β mAb in a KRAS-G12D-mutant mouse model of lung cancer led to tumor regression, which was associated with increased infiltration of CD8+ T cells, potentially due to a decrease in myeloid-cell-associated immunosuppression as well as inhibition of the NF-kB and STAT3 pathways [108]. This evidence concerns the gene KRAS and lung carcinoma.